AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02595034
Drug: BenzaClin® Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
Trial: NCT02595034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Trial: NCT04177303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to placebo
Trial: NCT04402047
Drug: Topical diclofenac sodium gel
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
Trial: NCT01993719
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day X 2 days intravenous (IV)
Trial: NCT01993719
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 to -3 (low-dose arm):30 mg/kg IV over 60 minutes for 2 days
Trial: NCT01993719
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 to -3 (low-dose arm): 300 mg/m\^2 IV over 60 minutes.
Trial: NCT04375631
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01103739
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
Trial: NCT01797718
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg/kg every 4 weeks for 6 months
Trial: NCT02586805
Drug: DX-2930 - 300mg/4wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Trial: NCT02586805
Drug: DX-2930 - 150mg/4wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
Trial: NCT02586805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every 2 weeks by subcutaneous injection.
Trial: NCT01569633
Drug: Metclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
Trial: NCT01569633
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of erythromycin is 1 miligram per kilogram every eight hours
Trial: NCT01569633
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of sugar water is 1 ml per 8 hours.
Trial: NCT02906553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04321460
Drug: LRG-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing live lyophilized probiotic bacteria of Lactobacillus genus
Trial: NCT04321460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing placebo
Trial: NCT00699192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule placebo to match valsartan orally once daily
Trial: NCT01221857
Drug: NiCord®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
Trial: NCT00224562
Drug: TNF-alpha antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03443830
Drug: Tyzivumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
Trial: NCT02502981
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg orally once a day for 40 weeks
Trial: NCT04241315
Drug: OTL38 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Trial: NCT01978119
Drug: FSC
RxNorm normalized name: Dofscort 3%-1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Trial: NCT01978119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
Trial: NCT00426478
Drug: Valsartan plus Hydrochlorothiazide (80mg/12.5mg)
RxNorm normalized name: hydrochlorothiazide / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03749226
Drug: Aztreonam lysine
RxNorm normalized name: aztreonam lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulization
Trial: NCT02526368
Drug: Hyperpolarized 13C,15N2-urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00158184
Drug: Placebo 0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg placebo dose administered once a day, orally.
Trial: NCT03467178
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy medication
Trial: NCT03254173
Drug: Placebo oral tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets , half tablet daily before sleep for 8 weeks
Trial: NCT03813030
Drug: Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion in clearance visit
Trial: NCT00426348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01871792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
Trial: NCT02351102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620020
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
Trial: NCT00706628
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01656525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous doses every 4 weeks for 24 weeks
Trial: NCT00452634
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40mg/QD, PO, daily, every 3 weeks
Trial: NCT01911364
Drug: BDP/FF/GB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superiority over Tiotropium
Trial: NCT01145560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00842933
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of corticosteroids 24 hours after cessation of vasopressors
Trial: NCT00842933
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
Trial: NCT00056199
Drug: EYE001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00882414
Drug: FERINJECT® (Ferric carboxymaltose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
Trial: NCT00882414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
Trial: NCT00943683
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
Trial: NCT03773952
Drug: PBF-677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
Trial: NCT03773952
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04672083
Drug: CPT31
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
Trial: NCT04672083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00511303
Drug: STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00215852
Drug: Alferon LDO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100microgram single intravitreal injection
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200microgram single intravitreal injection
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400microgram single intravitreal injection
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800microgram single intravitreal injection
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200microgram single intravitreal injection
Trial: NCT02323022
Drug: IAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
Trial: NCT02323022
Drug: IA regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
Trial: NCT00363714
Drug: AGN211745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600microgram single intravitreal injection
Trial: NCT00871481
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03404648
Drug: C-11 choline PET tracer
RxNorm normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
Trial: NCT00123929
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 every 3 weeks times 4
Trial: NCT02792257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose
Trial: NCT00622193
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT02117349
Drug: Rescue treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin-containing hemostats included in standard care at the site
Trial: NCT04246554
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketorolac for pain control following ACL reconstruction surgery
Trial: NCT04246554
Drug: Oxycodone-Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone-acetaminophen for post-operative pain control
Trial: NCT02768376
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
Trial: NCT02162888
Drug: Test Product (Bendamustine)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03010540
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Effect Of Fentanyl Only On Emergence Delirium
Trial: NCT02929524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Trial: NCT00135109
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05021718
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg) and Baclofen (10 mg) tablet twice a day for three weeks
Trial: NCT00496366
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
Trial: NCT01740336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to GDC-0941
Trial: NCT01886196
Drug: Non-steroidal anti-inflammatory drug (Ibuprofen)
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg of ibuprofen administered after exercise training session 3 days per week
Trial: NCT02109081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01915758
Drug: clindamycin1%/tretinoin 0.025% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clindamycin1%/tretinoin 0.025% gel
Trial: NCT01915758
Drug: vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle gel
Trial: NCT00432237
Drug: MK0974 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432237
Drug: MK0974 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432237
Drug: MK0974 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432237
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
Trial: NCT00627666
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00627666
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02582515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04337437
Drug: Genakumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/1ml/bottle, single subcutaneous injection.
Trial: NCT04337437
Drug: Placebo for this trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
Trial: NCT02514044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03420534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
Trial: NCT00331305
Drug: Placebo Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01319006
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
Trial: NCT01964248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied 2 hours before blood sample
Trial: NCT01964248
Drug: lidocaïne/prilocaïne 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
Trial: NCT00283387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.
Trial: NCT02236169
Drug: Atrovent CFC inhalation aerosol
RxNorm normalized name: Atrovent Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01319006
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
Trial: NCT00357773
Drug: Azithromycin (T1225)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03415165
Drug: green tea buccal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buccal tablet for 8 hrs 3 times aday
Trial: NCT03415165
Drug: Corticosteroids Topical
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: kenacort in orabase 4 times aday
Trial: NCT01319006
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
Trial: NCT02595242
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
Trial: NCT03406533
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Trial: NCT03406533
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Trial: NCT01238120
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg BID and 8 hours apart
Trial: NCT01238120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg BID and 8 hours apart
Trial: NCT01892488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD
Trial: NCT03759158
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet twice daily.
Trial: NCT03522129
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Study Drug
Trial: NCT03522129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active study drug
Trial: NCT02536586
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3023414 administered orally.
Trial: NCT02635204
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical application for 14 days.
Trial: NCT04552470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 matching placebo tablets taken twice a day (BID)
Trial: NCT03475225
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manufactured to mimic Cholecalciferol
Trial: NCT00058461
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT03285620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
Trial: NCT00030784
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no